$40m-$99.9m

Vor roars to $42m series A
Osage University Partners has contributed to a series A round for Vor Biopharma, an oncology drug developer based on work by Siddhartha Mukherjee at Columbia University.
Nuvaira shares $79m series E news
Nuvaira, based on research by a then-professor at Washington University School of Medicine, has closed a $79m funding round led by US Venture Partners.
Spin Memory banks Abies for series B
NYU and Allied Minds-founded Ram technology developer Spin Memory has unveiled deep tech-focused VC firm Abies Ventures as an investor in a $52m series B first announced late last year.
Bolt hits series B with $54m
Nan Fung Life Sciences and Novo have taken part in a series B round for Stanford's immuno-oncology drug developer Bolt Biotherapeutics.
Stanford gets in Sandbox for $68m round
Virtual reality entertainment operator Sandbox VR has amassed $68m in series A capital from investors including Stanford University.
Apic Bio picks up $40m
The series A funding will help UMass-founded genetic disease therapy developer Apic Bio progress targeted drugs for ALS and Alpha-1 antitrypsin deficiency.
Sanofi hands $91m to Biontech
Biontech, a spinout of Johannes Gutenberg University Mainz, has received $91.5m in funding as part of the extension of a deal to develop a cancer immunotherapy candidate with Sanofi.
Sophia Genetics generates $77m
The genomic testing platform developer has now raised some $140m, eight years after being co-founded in EPFL's Innovation Park by researchers from EMBL, Stanford and Geneva University.

Other News

Cabaletta Bio captures $50m
Autoimmune disease therapy spinout Cabaletta Bio's series B round brought its total to at least $88m allowed the university to pare back its shareholding.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Boosted hitches $60m series B ride
Stanford-StartX Fund has returned to pump funding into electric skateboard manufacturer Boosted, helping to take the company’s total funding to $70m.
Stanford's Annexon annexes $75m
Immunotherapy spinout Annexon Biosciences collected funding from Novartis Venture Fund in a series C round that brought its total funding to $154m.
Entrada darts to $59m series A round
MRL Ventures Fund and Roche Fund have taken part in the intracellular drug developer's series A, which is commercialising research by Prof Dehua Pei at OSU.
Synspective receives $2.7m boost
Synspective has been backed by a University of Tokyo VC vehicle in its bid to launch a constellation of 25 small Earth observation satellites powered by synthetic aperture radar.

Editor's Picks

Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
Kymeta satellites $50m
Kymeta Corporation, a satellite parts manufacturer, raises $50m series C with backing from consortium including multi-university venture fund Osage University Partners.
test reg

Login